Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02020343 · ClinicalTrials.gov registry record
Insulin Resistance in the Control of Intestinal Lipid Metabolism
A clinical trial, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- 22
- Enrollment target
NCT02020343: Completed study, sponsored by University of Missouri-Columbia.
NCT02020343 is a clinical trial that has completed, run by University of Missouri-Columbia. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02020343 has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
America's preferential consumption of high-fat/high-sugar foods is a driving force in the current epidemic of obesity and insulin resistance. Recent scientific observations suggest that the taste of food may play a role in how the body processes the food eaten in a meal. The intestine may play a central role in all aspects of dietary fat metabolism, from initial encounter with taste buds in the mouth to eventual triglyceride (TG) storage in the body. The investigators hypothesize that elevated blood fats in insulin resistance are a result of elevated intestinal-TG secretion and poor communication of this organ to the rest of the body after meals. In this study, meal feeding and sensory studies will be performed to determine whether the mechanism of taste-associated intestinal signaling leads to higher levels of blood fats after meals in 24 healthy, insulin resistant and type 2 diabetic subjects. Individuals will consume special meals the night before the tests and participate in sensory tests in the morning to analyze the effect of taste. The goal of this work is to understand how insulin resistance may cause impaired signaling between the taste buds and the intestine to result in an elevation in blood lipids, which increases the risk for other chronic diseases. This study will generate data for a future study to understand how diabetes treatment affects this process.
Primary Outcome
In vivo measurement of meal TG absorption is made using stable isotope administration into sequential meals (lunch and dinner) and analysis of plasma samples by GS/MS
Interventions
- BEHAVIORAL taste tests
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-08 |
What the finished NCT02020343 record still lists
NCT02020343 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which taste tests is the first listed.
NCT02020343 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02020343 about?
NCT02020343 is a clinical study titled "Insulin Resistance in the Control of Intestinal Lipid Metabolism". America's preferential consumption of high-fat/high-sugar foods is a driving force in the current epidemic of obesity and insulin resistance. Recent scientific observations suggest that the taste of food may play a role in how the body processes the food eaten in a meal. The intestine may play a cen...
What is the current status of trial NCT02020343?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2014-01. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02020343?
The interventions under investigation include: taste tests (BEHAVIORAL).
Who is sponsoring clinical trial NCT02020343?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia